In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo

Molecular Pharmacology

Volumn 86, Issue 5, 2014, Pages 593-608

  Parks, Ashley J ^a,b   Pollastri, Michael P ^c   Hahn, Mark E ^e   Stanford, Elizabeth A ^a,b   Novikov, Olga ^a,b   Franks, Diana G ^e   Haigh, Sarah E ^f   Narasimhan, Supraja ^b   Ashton, Trent D ^d   Hopper, Timothy G ^c   Kozakov, Dmytro ^d   Beglov, Dimitri ^d   Vajda, Sandor ^d   Schlezinger, Jennifer J ^b   Sherr, David H ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d BOSTON UNIVERSITY   (United States)

^e WOODS HOLE OCEANOGRAPHIC INSTITUTION   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL N [2 METHYL 4 (O TOLYLDIAZENYL)PHENYL] 1H PYRAZOLE 2 CARBOXAMIDE; 2 (BENZYLOXY) N (5 ETHYL 1,3,4 THIADIAZOL 2 YL)BENZAMIDE; 2 PHENYL 5,6,7,8 TETRAHYDRO 4H CHROMEN 4 THIONE; 2 [(4 FLUOROBENZYL)OXY] N (5 ISOPROPYL 1,3,4 THIADIAZOL 2 YL)BENZAMIDE; 2 [[2 (5 BROMOFURAN 2 YL) 4 OXO 4H CHROMEN 3 YL]OXY]ACETAMIDE; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; IMMUNOMODULATING AGENT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; BIOLOGICAL FACTOR; LIGAND;

ADAPTIVE IMMUNITY; ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTAGONIST POTENCY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COMPETITIVE INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CONFORMATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; EC50; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SCREENING; IC50; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; LIGAND BINDING; LIPOPHILICITY; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; TITRIMETRY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; WOUND CLOSURE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; C57BL MOUSE; CELL LINE; CELL MOTION; CELL PROLIFERATION; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; HUMAN; STROMA CELL; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL FACTORS; BONE MARROW CELLS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; LIGANDS; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, ARYL HYDROCARBON; STROMAL CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84922272693     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.093369     Document Type: Article

References (73)

1. Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, and Kuchroo VK (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11:854-861.
2. Barhoover MA, Hall JM, Greenlee WF, and Thomas RS (2010) Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol Pharmacol 77:195-201.
3. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S et al. (2002) The Protein Data Bank. Acta Crystallogr D Biol Crystallogr 58:899-907.
4. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR, Flaveny CA, Perdew GH, and Denison MS et al. (2010) Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329:1345-1348.
5. Brenke R, Kozakov D, Chuang GY, Beglov D, Hall D, Landon MR, Mattos C, and Vajda S (2009) Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics 25:621-627.
6. Brooks B, Bruccoleri R, Olafson B, States D, Swaminathan S, and Karplus M (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4:187-217.
7. Brooks J and Eltom SE (2011) Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor. Curr Cancer Drug Targets 11:654-669.
8. Burbach KM, Poland A, and Bradfield CA (1992) Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci USA 89:8185-8189.
9. Carlin SM, Ma DD, and Moore JJ (2013) T-cell potential of human adult and cord blood hemopoietic stem cells expanded with the use of aryl hydrocarbon receptor antagonists. Cytotherapy 15:224-230.
10. Caruso JA, Mathieu PA, Joiakim A, Leeson B, Kessel D, Sloane BF, and Reiners JJ, Jr (2004) Differential susceptibilities of murine hepatoma 1c1c7 and Tao cells to the lysosomal photosensitizer NPe6: influence of aryl hydrocarbon receptor on lysosomal fragility and protease contents. Mol Pharmacol 65:1016-1028.
11. Caruso JA, Mathieu PA, Joiakim A, Zhang H, and Reiners JJ, Jr (2006) Aryl hydrocarbon receptor modulation of TNFalpha -induced apoptosis and lysosomal disruption in a hepatoma model that is caspase-8 independent. J Biol Chem 281:10954-10967.
12. Casado FL, Singh KP, and Gasiewicz TA (2010) The aryl hydrocarbon receptor: regulation of hematopoiesis and involvement in the progression of blood diseases. Blood Cells Mol Dis 44:199-206.
13. Dietrich C and Kaina B (2010) The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 31:1319-1328.
14. Dolwick KM, Schmidt JV, Carver LA, Swanson HI, and Bradfield CA (1993) Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol 44:911-917.
15. Dubrovska A, Hartung A, Bouchez LC, Walker JR, Reddy VA, Cho CY, and Schultz PG (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 107:43-52.
16. Dvorak Z, Vrzal R, Henklova P, Jancova P, Anzenbacherova E, Maurel P, Svecova L, Pavek P, Ehrmann J, and Havlik R et al. (2008) JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes. Biochem Pharmacol 75:580-588.
17. Fiser A and Sali A (2003) Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol 374:461-491.
18. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, and Quintana FJ (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11:846-853.
19. Goode GD, Ballard BR, Manning HC, Freeman ML, Kang Y, and Eltom SE (2013) Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line. Int J Cancer 133:2769-2780.
20. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, and Schwabe JW et al. (2000) A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 275:5754-5759.
21. Hall JM, Barhoover MA, Kazmin D, McDonnell DP, Greenlee WF, and Thomas RS (2010) Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol 24:359-369.
22. Hankinson O, Brooks BA, Weir-Brown KI, Hoffman EC, Johnson BS, Nanthur J, Reyes H, and Watson AJ (1991) Genetic and molecular analysis of the Ah receptor and of Cyp1a1 gene expression. Biochimie 73:61-66.
23. Hardy RR and Hayakawa K (2001) B cell development pathways. Annu Rev Immunol 19:595-621.
24. Hawkins PC and Nicholls A (2012) Conformer generation with OMEGA: learning from the data set and the analysis of failures. J Chem Inf Model 52:2919-2936.
25. Hawkins PCD, Skillman AG, and Nicholls A (2007) Comparison of shape-matching and docking as virtual screening tools. J Med Chem 50:74-82.
26. Hughes L, Malone C, Chumsri S, Burger AM, and McDonnell S (2008) Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis 25:549-557.
27. Karchner SI, Franks DG, Kennedy SW, and Hahn ME (2006) The molecular basis for differential dioxin sensitivity in birds: role of the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 103:6252-6257.
28. Kerkvliet NI, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D, and Mourich DV (2009) Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 1:539-547.
29. Kim SH, Henry EC, Kim DK, Kim YH, Shin KJ, Han MS, Lee TG, Kang JK, Gasiewicz TA, and Ryu SH et al. (2006) Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol 69:1871-1878.
30. Kiss EA, Vonarbourg C, Kopfmann S, Hobeika E, Finke D, Esser C, and Diefenbach A (2011) Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science 334:1561-1565.
31. Kozakov D, Hall DR, Chuang GY, Cencic R, Brenke R, Grove LE, Beglov D, Pelletier J, Whitty A, and Vajda S (2011) Structural conservation of druggable hot spots in protein-protein interfaces. Proc Natl Acad Sci USA 108:13528-13533.
32. Lahoti TS, John K, Hughes JM, Kusnadi A, Murray IA, Krishnegowda G, Amin S, and Perdew GH (2013) Aryl hydrocarbon receptor antagonism mitigates cytokine-mediated inflammatory signalling in primary human fibroblast-like synoviocytes. Ann Rheum Dis 72:1708-1716.
33. Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, Mantovani A, Kopan R, Bradfield CA, and Newberry RD et al. (2012) AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 13:144-151.
34. Li NY, Weber CE, Wai PY, Cuevas BD, Zhang J, Kuo PC, and Mi Z (2013) An MAPK-dependent pathway induces epithelial-mesenchymal transition via Twist activation in human breast cancer cell lines. Surgery 154:404-410.
35. Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, Wilhelm C, and Veldhoen M (2011) Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147:629-640.
36. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
37. Lu YF, Santostefano M, Cunningham BD, Threadgill MD, and Safe S (1996) Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. Biochem Pharmacol 51:1077-1087.
38. Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, and O'Hara C et al. (2003) The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102:3287-3294.
39. Mann KK, Matulka RA, Hahn ME, Trombino AF, Lawrence BP, Kerkvliet NI, and Sherr DH (1999) The role of polycyclic aromatic hydrocarbon metabolism in dimethylbenz[a]anthracene-induced pre-B lymphocyte apoptosis. Toxicol Appl Pharmacol 161:10-22.
40. Motto I, Bordogna A, Soshilov AA, Denison MS, and Bonati L (2011) New aryl hydrocarbon receptor homology model targeted to improve docking reliability. J Chem Inf Model 51:2868-2881.
41. Murray GI, Patimalla S, Stewart KN, Miller ID, and Heys SD (2010) Profiling the expression of cytochrome P450 in breast cancer. Histopathology 57:202-211.
42. Murray IA, Flaveny CA, DiNatale BC, Chairo CR, Schroeder JC, Kusnadi A, and Perdew GH (2009) Antagonism of aryl hydrocarbon receptor signaling by 6,2′,4′-trimethoxyflavone. J Pharmacol Exp Ther 332:135-144.
43. N'jai AU, Larsen MC, Bushkofsky JR, Czuprynski CJ, and Jefcoate CR (2011) Acute disruption of bone marrow hematopoiesis by benzo(a)pyrene is selectively reversed by aryl hydrocarbon receptor-mediated processes. Mol Pharmacol 79:724-734.
44. Nagy SR, Sanborn JR, Hammock BD, and Denison MS (2002) Development of a green fluorescent protein-based cell bioassay for the rapid and inexpensive detection and characterization of ah receptor agonists. Toxicol Sci 65:200-210.
45. Nebert DW, Petersen DD, and Puga A (1991) Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1:68-78.
46. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, and Weller M et al. (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197-203.
47. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
48. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, and Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453:65-71.
49. Quintana FJ, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, Rangachari M, Zhu C, Xiao S, and Seavitt J et al. (2012) Aiolos promotes TH17 differentiation by directly silencing Il2 expression.Nat Immunol 13:770-777.
50. Santostefano M, Merchant M, Arellano L, Morrison V, Denison MS, and Safe S (1993) alpha-Naphthoflavone-induced CYP1A1 gene expression and cytosolic aryl hydrocarbon receptor transformation. Mol Pharmacol 43:200-206.
51. Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK, and Gardner KH (2009) Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci USA 106:450-455.
52. Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, and Frantz DE et al. (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9:271-276.
53. Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE, and Sherr DH (2006) A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem 387:1175-1187.
54. Shin SR, Sánchez-Velar N, Sherr DH, and Sonenshein GE (2006) 7,12-dimethylbenz (a)anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factor-kappaB. Cancer Res 66:2570-2575.
55. Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, and Chui DH et al. (2013) The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood 122:376-385.
56. Smith KJ, Murray IA, Tanos R, Tellew J, Boitano AE, Bisson WH, Kolluri SK, Cooke MP, and Perdew GH (2011) Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism. J Pharmacol Exp Ther 338:318-327.
57. Sukhumavasi W, Egan CE, and Denkers EY (2007) Mouse neutrophils require JNK2 MAPK for Toxoplasma gondii-induced IL-12p40 and CCL2/MCP-1 release. J Immunol 179:3570-3577.
58. Teague JE, Ryu H-Y, Kirber M, Sherr DH, and Schlezinger JJ (2010) Proximal events in 7,12-dimethylbenz[a]anthracene-induced, stromal cell-dependent bone marrow B cell apoptosis: stromal cell-B cell communication and apoptosis signaling. J Immunol 185:3369-3378.
59. Trombino AF, Near RI, Matulka RA, Yang S, Hafer LJ, Toselli PA, Kim DW, Rogers AE, Sonenshein GE, and Sherr DH (2000) Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res Treat 63:117-131.
60. Trott O and Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455-461.
61. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, and Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453:106-109.
62. Veldhoen M, Hirota K, Christensen J, O'Garra A, and Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206:43-49.
63. Wu D, Nishimura N, Kuo V, Fiehn O, Shahbaz S, Van Winkle L, Matsumura F, and Vogel CF (2011) Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol 31:1260-1267.
64. Wu D, Potluri N, Kim Y, and Rastinejad F (2013) Structure and dimerization properties of the aryl hydrocarbon receptor PAS-A domain. Mol Cell Biol 33:4346-4356.
65. Xing Y, Nukaya M, Satyshur KA, Jiang L, Stanevich V, Korkmaz EN, Burdette L, Kennedy GD, Cui Q, and Bradfield CA (2012) Identification of the Ah-receptor structural determinants for ligand preferences. Toxicol Sci 129:86-97.
66. Xu M and Miller MS (2004) Determination of murine fetal Cyp1a1 and 1b1 expression by real-time fluorescence reverse transcription-polymerase chain reaction. Toxicol Appl Pharmacol 201:295-302.
67. Yang X, Liu D, Murray TJ, Mitchell GC, Hesterman EV, Karchner SI, Merson RR, Hahn ME, and Sherr DH (2005) The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cells. Oncogene 24:7869-7881.
68. Yang X, Solomon S, Fraser LR, Trombino AF, Liu D, Sonenshein GE, Hestermann EV, and Sherr DH (2008) Constitutive regulation of CYP1B1 by the aryl hydrocarbon receptor (AhR) in pre-malignant and malignant mammary tissue. J Cell Biochem 104:402-417.
69. Zhang S, Lei P, Liu X, Li X, Walker K, Kotha L, Rowlands C, and Safe S (2009) The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. Endocr Relat Cancer 16:835-844.
70. Zhang S, Qin C, and Safe SH (2003) Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 111:1877-1882.
71. Zhao B, Degroot DE, Hayashi A, He G, and Denison MS (2010) CH223191 is a ligand-selective antagonist of the Ah (Dioxin) receptor. Toxicol Sci 117:393-403.
72. Zhao S, Kanno Y, Nakayama M, Makimura M, Ohara S, and Inouye Y (2012) Activation of the aryl hydrocarbon receptor represses mammosphere formation in MCF-7 cells. Cancer Lett 317:192-198.
73. Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, Gonzalez N, Martínez A, Narayan G, Kirsch I, and Franklin W et al. (2008) The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest 118:640-650.